Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.

diagnostic yield dystonia exome sequencing prediction rare disease scoring algorithm

Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
08 2021
Historique:
revised: 22 02 2021
received: 06 11 2020
accepted: 26 03 2021
pubmed: 6 5 2021
medline: 1 9 2021
entrez: 5 5 2021
Statut: ppublish

Résumé

Despite the established value of genomic testing strategies, practice guidelines for their use do not exist in many indications. We sought to validate a recently introduced scoring algorithm for dystonia, predicting the diagnostic utility of whole-exome sequencing (WES) based on individual phenotypic aspects (age-at-onset, body distribution, presenting comorbidity). We prospectively enrolled a set of 209 dystonia-affected families and obtained summary scores (0-5 points) according to the algorithm. Singleton (N = 146), duo (N = 11), and trio (N = 52) WES data were generated to identify genetic diagnoses. Diagnostic yield was highest (51%) among individuals with a summary score of 5, corresponding to a manifestation of early-onset segmental or generalized dystonia with coexisting non-movement disorder-related neurological symptoms. Sensitivity and specificity at the previously suggested threshold for implementation of WES (3 points) was 96% and 52%, with area under the curve of 0.81. The algorithm is a useful predictive tool and could be integrated into dystonia routine diagnostic protocols. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Sections du résumé

BACKGROUND
Despite the established value of genomic testing strategies, practice guidelines for their use do not exist in many indications.
OBJECTIVES
We sought to validate a recently introduced scoring algorithm for dystonia, predicting the diagnostic utility of whole-exome sequencing (WES) based on individual phenotypic aspects (age-at-onset, body distribution, presenting comorbidity).
METHODS
We prospectively enrolled a set of 209 dystonia-affected families and obtained summary scores (0-5 points) according to the algorithm. Singleton (N = 146), duo (N = 11), and trio (N = 52) WES data were generated to identify genetic diagnoses.
RESULTS
Diagnostic yield was highest (51%) among individuals with a summary score of 5, corresponding to a manifestation of early-onset segmental or generalized dystonia with coexisting non-movement disorder-related neurological symptoms. Sensitivity and specificity at the previously suggested threshold for implementation of WES (3 points) was 96% and 52%, with area under the curve of 0.81.
CONCLUSIONS
The algorithm is a useful predictive tool and could be integrated into dystonia routine diagnostic protocols. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Identifiants

pubmed: 33949708
doi: 10.1002/mds.28614
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1959-1964

Informations de copyright

© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Références

Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med 2018;3:16.
Rexach J, Lee H, Martinez-Agosto JA, Nemeth AH, Fogel BL. Clinical application of next-generation sequencing to the practice of neurology. Lancet Neurol 2019;18(5):492-503.
Trujillano D, Bertoli-Avella AM, Kumar Kandaswamy K, et al. Clinical exome sequencing: results from 2819 samples reflecting 1000 families. Eur J Hum Genet 2017;25(2):176-182.
Sun M, Johnson AK, Nelakuditi V, et al. Targeted exome analysis identifies the genetic basis of disease in over 50% of patients with a wide range of ataxia-related phenotypes. Genet Med 2019;21(1):195-206.
Trinh J, Lohmann K, Baumann H, et al. Utility and implications of exome sequencing in early-onset Parkinson's disease. Mov Disord 2019;34(1):133-137.
Krenn M, Wagner M, Hotzy C, et al. Diagnostic exome sequencing in non-acquired focal epilepsies highlights a major role of GATOR1 complex genes. J Med Genet 2020;57(9):624-633.
Topf A, Johnson K, Bates A, et al. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness. Genet Med 2020;22(9):1478-1488.
Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med 2014;16(2):176-182.
Vrijenhoek T, Middelburg EM, Monroe GR, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur J Hum Genet 2018;26(11):1566-1571.
Zech M, Jech R, Boesch S, et al. Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurol 2020;19(11):908-918.
Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28(7):863-873.
Albanese A, Bhatia K, DeLong MR, et al. "Complex" dystonia is not a category in the new 2013 consensus classification. Mov Disord 2016;31(11):1758-1759.
Zech M, Boesch S, Jochim A, et al. Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-up. Mov Disord 2017;32(4):549-559.
Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 2016;44(D1):D862-D868.
Stenson PD, Mort M, Ball EV, et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017;136(6):665-677.
Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 2005;33(Database issue):D514-D517.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405-424.
Bouhouche A, Tibar H, Ben El Haj R, et al. LRRK2 G2019S mutation: prevalence and clinical features in Moroccans with Parkinson's disease. Parkinsons Dis 2017;2017:2412486.
Appel-Cresswell S, Guella I, Lehman A, Foti D, Farrer MJ. PSEN1 p.Met233Val in a complex neurodegenerative movement and neuropsychiatric disorder. J Mov Disord 2018;11(1):45-48.
Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21(1):128-138.
Wirth T, Tranchant C, Drouot N, et al. Increased diagnostic yield in complex dystonia through exome sequencing. Parkinsonism Relat Disord 2020;74:50-56.
Olgiati S, Quadri M, Bonifati V. Genetics of movement disorders in the next-generation sequencing era. Mov Disord 2016;31(4):458-470.

Auteurs

Michael Zech (M)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Robert Jech (R)

Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.

Sylvia Boesch (S)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Matej Škorvánek (M)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Ján Necpál (J)

Department of Neurology, Zvolen Hospital, Zvolen, Slovakia.

Jana Švantnerová (J)

Second Department of Neurology, Faculty of Medicine, Comenius University, University Hospital Bratislava, Bratislava, Slovakia.

Matias Wagner (M)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Ariane Sadr-Nabavi (A)

Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Qaem Medical Center, Mashhad, Iran.
Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran.

Felix Distelmaier (F)

Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.

Martin Krenn (M)

Institute of Human Genetics, Technical University of Munich, Munich, Germany.
Department of Neurology, Medical University of Vienna, Vienna, Austria.

Tereza Serranová (T)

Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.

Irena Rektorová (I)

First Department of Neurology, Faculty of Medicine, St. Anne's University Hospital and CEITEC, Masaryk University, Brno, Czech Republic.

Petra Havránková (P)

Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.

Alexandra Mosejová (A)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Iva Příhodová (I)

Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.

Jana Šarláková (J)

Department of Neurology, University Hospital, Hradec Kralove, Czech Republic.

Kristína Kulcsarová (K)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Olga Ulmanová (O)

Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.

Karel Bechyně (K)

Hospital Písek, Písek, Czech Republic.

Miriam Ostrozovičová (M)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Vladimír Haň (V)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Joaquim Ribeiro Ventosa (JR)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Theresa Brunet (T)

Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Riccardo Berutti (R)

Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Mohammad Shariati (M)

Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Qaem Medical Center, Mashhad, Iran.
Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran.

Ali Shoeibi (A)

Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Qaem Medical Center, Mashhad, Iran.

Susanne A Schneider (SA)

Department of Neurology, Ludwig-Maximilians-University, Munich, Germany.

Alice Kuster (A)

Inborn Errors of Metabolism, Pediatric Intensive Care Unit, University Hospital of Nantes, Nantes, France.

Matthias Baumann (M)

Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria.

David Weise (D)

Klinik für Neurologie, Asklepios Fachklinikum Stadtroda, Stadtroda, Germany.

Friederike Wilbert (F)

Department of Neuropediatrics and Muscle Disorders, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Wibke G Janzarik (WG)

Department of Neuropediatrics and Muscle Disorders, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Matthias Eckenweiler (M)

Department of Neuropediatrics and Muscle Disorders, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Volker Mall (V)

Lehrstuhl für Sozialpädiatrie, Technische Universität München, Munich, Germany.
kbo-Kinderzentrum München, Munich, Germany.

Bernhard Haslinger (B)

Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Steffen Berweck (S)

Ludwig Maximilian University of Munich, Munich, Germany.
Hospital for Neuropediatrics and Neurological Rehabilitation, Centre of Epilepsy for Children and Adolescents, Schoen Klinik Vogtareuth, Vogtareuth, Germany.

Juliane Winkelmann (J)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Institute of Human Genetics, Technical University of Munich, Munich, Germany.
Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Konrad Oexle (K)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Institute of Human Genetics, Technical University of Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH